Naltrexone
"Naltrexone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
Descriptor ID |
D009271
|
MeSH Number(s) |
D03.132.577.249.706.550 D03.605.497.750.550 D03.633.400.686.750.550 D04.615.723.795.706.550
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Naltrexone".
Below are MeSH descriptors whose meaning is more specific than "Naltrexone".
This graph shows the total number of publications written about "Naltrexone" by people in this website by year, and whether "Naltrexone" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 1 | 2 | 1997 | 1 | 0 | 1 | 1998 | 0 | 1 | 1 | 1999 | 2 | 1 | 3 | 2000 | 0 | 1 | 1 | 2003 | 1 | 0 | 1 | 2007 | 3 | 0 | 3 | 2008 | 3 | 0 | 3 | 2010 | 2 | 0 | 2 | 2012 | 1 | 0 | 1 | 2013 | 2 | 0 | 2 | 2014 | 0 | 2 | 2 | 2015 | 3 | 1 | 4 | 2016 | 0 | 3 | 3 | 2017 | 1 | 0 | 1 | 2018 | 6 | 3 | 9 | 2019 | 2 | 1 | 3 | 2020 | 4 | 1 | 5 | 2021 | 1 | 1 | 2 | 2022 | 0 | 2 | 2 | 2023 | 3 | 4 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Naltrexone" by people in Profiles.
-
Gibbons JB, McCullough JS, Zivin K, Brown ZY, Norton EC. Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare. J Subst Use Addict Treat. 2024 Feb; 157:209271.
-
Radi R, Huang H, Rivera J, Lyon C, DeSanto K. Is low-dose naltrexone effective in chronic pain management? J Fam Pract. 2023 09; 72(7):320-321.
-
Gowin JL, Sloan ME, Kirk-Provencher KT, Rosenblatt SL, Penner AE, Stangl BL, Byrd ND, Swan JE, Ramchandani VA. Opioid receptor antagonism and neural response to monetary rewards: Pilot studies in light and heavy alcohol users. J Psychopharmacol. 2023 09; 37(9):937-941.
-
Krantz MJ, Rudo TJ, Haigney MCP, Stockbridge N, Kleiman RB, Klein M, Kao DP. Ventricular Arrhythmias Associated With?Over-the-Counter and Recreational?Opioids. J Am Coll Cardiol. 2023 06 13; 81(23):2258-2268.
-
Brown KT, Levis SC, O'Neill CE, Levy C, Rice KC, Watkins LR, Bachtell RK. Toll-like receptor 4 antagonists reduce cocaine-primed reinstatement of drug seeking. Psychopharmacology (Berl). 2023 Jul; 240(7):1587-1600.
-
Deaney M, Terasaki D. Intramuscular, extended-release naltrexone inadvertently administered in the deltoid muscle: A case report. J Am Pharm Assoc (2003). 2023 Jul-Aug; 63(4):1245-1248.
-
Terasaki D. Self-reported Past Experiences With Naltrexone and Attitudes Toward Daily Adherence Among High-utilization Patients With Alcohol Use Disorder. J Addict Med. 2023 May-Jun 01; 17(3):371-372.
-
Terasaki D, Loh R, Cornell A, Taub J, Thurstone C. Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates. Addict Sci Clin Pract. 2022 Nov 22; 17(1):64.
-
Chockalingam L, Burnham EL, Jolley SE. Medication prescribing for alcohol use disorders during alcohol-related encounters in a Colorado regional healthcare system. Alcohol Clin Exp Res. 2022 06; 46(6):1094-1102.
-
Schacht JP, Hoffman M, Chen BH, Anton RF. Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial. Pharmacogenomics J. 2022 02; 22(1):1-8.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|